Brian Savage (TEVA) reports RSU vesting and three share sales, including $41K disposition

Rhea-AI Filing Summary

Brian Savage reports proposed sales of Teva ordinary shares and an upcoming RSU vesting. The filing lists three dispositions: 450 shares on 01/30/2026 for $15,178.95, 1,000 shares on 12/12/2025 for $29,910.70, and 1,274 shares on 03/03/2026 for $41,226.51.

The notice also shows 3,580 restricted share units vesting on 03/05/2026 described as a compensation award.

Insights

Corporate Governance Analyst

Routine affiliate sale notice with an upcoming RSU vesting; no material company-level change.

The filing documents specific share dispositions: $15,178.95, $29,910.70, and $41,226.51 tied to sales on 12/12/2025, 01/30/2026, and 03/03/2026. These are individual transactions by Brian Savage and are typical of Rule 144 notices.

It also lists 3,580 restricted share units vesting on 03/05/2026. Cash‑flow treatment and whether proceeds go to the issuer are not stated in the excerpt; subsequent filings may clarify disposition mechanics.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	1127	35690.24	1149812898	03/05/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/05/2025	RESTRICTED SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			3580	03/05/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
BRIAN SAVAGE 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	01/30/2026	450	15178.95
BRIAN SAVAGE 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	12/12/2025	1000	29910.70
BRIAN SAVAGE 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020	ORDINARY SHARES	03/03/2026	1274	41226.51

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does TEVA Form 144 filed by Brian Savage disclose?

It discloses proposed sales of Teva ordinary shares and an RSU vesting. The filing lists three dispositions totaling 2,724 shares with specific dates and dollar amounts, and 3,580 restricted share units vesting on 03/05/2026.

How many Teva shares did Brian Savage report selling in recent transactions?

The filing lists three sales totaling 2,724 shares. Transactions: 1,000 (12/12/2025), 450 (01/30/2026), and 1,274 (03/03/2026) with the dollar amounts shown in the notice.

When do the restricted share units for TEVA vest according to the filing?

The filing shows 3,580 restricted share units vesting on 03/05/2026. They are labeled as a compensation award in the securities-to-be-sold section.

Do the Form 144 entries state who receives the sale proceeds for TEVA?

No explicit recipient of proceeds is provided in the excerpt. The entries list transaction dates, share counts, and dollar amounts but do not state whether proceeds go to the issuer or the selling holder.